Recent findings propose that Retatrutide , a dual agonist targeting GLP-1 and GIP receptors , may represent a significant progress for body management . Initial patient investigations shown https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide